provide an update on the current FDA and European Medicines Agency warnings about the aortic risks associated with fluoroquinolones

describe the evolution of decision making regarding surgical treatment of genetically-triggered thoracic aortic disease, including the current gene variant-based approach and future opportunities to make decisions based on integrated multidimensional patient-specific data